Role of proadrenomedullin in the progression of diabetic kidney disease in patients with type 2 diabetes mellitus

Background. Type 2 diabetes mellitus (T2DM) is a chro­nic disease with increasing prevalence. Metabolic changes and inflammation caused by hyperglycemia in T2DM lead to deterioration of kidney function. Diabetic kidney disease (DKD), a common complication of T2DM, is a leading cause of end-stage ren...

Full description

Saved in:
Bibliographic Details
Main Authors: A.M. Urbanovych, A.P. Vereshchynska
Format: Article
Language:English
Published: Zaslavsky O.Yu. 2024-06-01
Series:Mìžnarodnij Endokrinologìčnij Žurnal
Subjects:
Online Access:https://iej.zaslavsky.com.ua/index.php/journal/article/view/1404
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849221483915640832
author A.M. Urbanovych
A.P. Vereshchynska
author_facet A.M. Urbanovych
A.P. Vereshchynska
author_sort A.M. Urbanovych
collection DOAJ
description Background. Type 2 diabetes mellitus (T2DM) is a chro­nic disease with increasing prevalence. Metabolic changes and inflammation caused by hyperglycemia in T2DM lead to deterioration of kidney function. Diabetic kidney disease (DKD), a common complication of T2DM, is a leading cause of end-stage renal di­sease. We investigated the prognostic value of proadrenomedullin (Pro-ADM) as an unconventional biomarker of renal impairment progression in patients with T2DM. The purpose was to investigate the role of proadrenomedullin in the progression of DKD in people with T2DM. Materials and methods. Eighty-six patients with T2DM and DKD were examined. The study was conducted at the Lviv Regional State Clinical Medical and Diagnostic Endocrinological Center, a clinical base of the Department of Endocrinology of the Danylo Halytsky Lviv National Medical University. Patients were divided into 3 groups according to the degrees of DKD risk progression. In addition to standardized clinical and laboratory tests, the concentration of Pro-ADM in blood serum was evaluated. The obtained data were processed statistically with an assessment of probability and correlation. Results. The level of Pro-ADM in patients with T2DM and DKD varied statistically significant depen­ding on the risk of DKD progression. In group 1, its average content was 19.65 ± 0.98 pmol/l, in group 2 — 35.15 ± 2.46 pmol/l, and in group 3 — 72.02 ± 2.82 pmol/l. The results showed a significant increase in Pro-ADM with DKD progression (p < 0.001). A correlation analysis was performed between Pro-ADM and patients’ age, duration of disease, HbA1c, total cholesterol, urea, creatinine, estimated glomerular filtration rate (eGFR) levels, and albumin-creatinine ratio (ACR). In group 1, a positive weak correlation was found between Pro-ADM and age (R = 0.02; p < 0.01); cholesterol (R = 0.03; p > 0.05); urea (R1 = 0.17; p < 0.01); creatinine levels (R = 0.12; p < 0.01); and ACR (R = 0.16; p < 0.01). There was a positive moderate correlation with the duration of T2DM (R = 0.39; p < 0.05) and HbA1c level (R = 0.31; p < 0.05) and a moderate negative correlation with eGFR (R = –0.51; p < 0.01). In group 2, a positive weak correlation of Pro-ADM with age (R = 0.12; p < 0.01); duration of T2DM (R = 0.28; p < 0.05); cholesterol (R = 0.06; p > 0.05), and urea levels (R = 0.06; p > 0.05) was observed. There was a positive moderate correlation with HbA1c (R = 0.31; p < 0.05); creatinine (R = 0.47; p < 0.01) levels, and ACR (R = 0.32; p < 0.01). A mode­rate inverse correlation with eGFR was also found (R = –0.33; p < 0.01). In group 3, a posi­tive weak correlation of Pro-ADM with the duration of T2DM (R = 0.24; p < 0.05), and total cholesterol level (R = 0.19; p > 0.05) was observed. A positive mode­rate correlation with age (R = 0.53; p < 0.01); HbA1c (R = 0.33; p < 0.05), urea (R = 0.42; p > 0.05), creatinine levels (R = 0.34; p < 0.01), and ACR (R = 0.36; p < 0.01) was found. There was also a negative strong correlation with eGFR (R = –0.71; p < 0.01). Conclusions. We found a significant increase in Pro-ADM level in patients with T2DM depending on the progression of DKD. The revealed correlations between Pro-ADM and clinical parameters of T2DM and the functional state of the kidneys indicate that the level of Pro-ADM is associated with the progression of DKD. These results show the importance of identifying Pro-ADM as a potential marker for assessing the progression of renal impairment in patients with T2DM.
format Article
id doaj-art-7e4fcbe463474db08407cb14906d9bd2
institution Kabale University
issn 2224-0721
2307-1427
language English
publishDate 2024-06-01
publisher Zaslavsky O.Yu.
record_format Article
series Mìžnarodnij Endokrinologìčnij Žurnal
spelling doaj-art-7e4fcbe463474db08407cb14906d9bd22024-11-10T19:05:51ZengZaslavsky O.Yu.Mìžnarodnij Endokrinologìčnij Žurnal2224-07212307-14272024-06-0120426627110.22141/2224-0721.20.4.2024.14041402Role of proadrenomedullin in the progression of diabetic kidney disease in patients with type 2 diabetes mellitusA.M. Urbanovych0https://orcid.org/0000-0003-3676-7345A.P. Vereshchynska1https://orcid.org/0000-0001-9643-7589Danylo Halytsky Lviv National Medical University, Lviv, UkraineDanylo Halytsky Lviv National Medical University, Lviv, UkraineBackground. Type 2 diabetes mellitus (T2DM) is a chro­nic disease with increasing prevalence. Metabolic changes and inflammation caused by hyperglycemia in T2DM lead to deterioration of kidney function. Diabetic kidney disease (DKD), a common complication of T2DM, is a leading cause of end-stage renal di­sease. We investigated the prognostic value of proadrenomedullin (Pro-ADM) as an unconventional biomarker of renal impairment progression in patients with T2DM. The purpose was to investigate the role of proadrenomedullin in the progression of DKD in people with T2DM. Materials and methods. Eighty-six patients with T2DM and DKD were examined. The study was conducted at the Lviv Regional State Clinical Medical and Diagnostic Endocrinological Center, a clinical base of the Department of Endocrinology of the Danylo Halytsky Lviv National Medical University. Patients were divided into 3 groups according to the degrees of DKD risk progression. In addition to standardized clinical and laboratory tests, the concentration of Pro-ADM in blood serum was evaluated. The obtained data were processed statistically with an assessment of probability and correlation. Results. The level of Pro-ADM in patients with T2DM and DKD varied statistically significant depen­ding on the risk of DKD progression. In group 1, its average content was 19.65 ± 0.98 pmol/l, in group 2 — 35.15 ± 2.46 pmol/l, and in group 3 — 72.02 ± 2.82 pmol/l. The results showed a significant increase in Pro-ADM with DKD progression (p < 0.001). A correlation analysis was performed between Pro-ADM and patients’ age, duration of disease, HbA1c, total cholesterol, urea, creatinine, estimated glomerular filtration rate (eGFR) levels, and albumin-creatinine ratio (ACR). In group 1, a positive weak correlation was found between Pro-ADM and age (R = 0.02; p < 0.01); cholesterol (R = 0.03; p > 0.05); urea (R1 = 0.17; p < 0.01); creatinine levels (R = 0.12; p < 0.01); and ACR (R = 0.16; p < 0.01). There was a positive moderate correlation with the duration of T2DM (R = 0.39; p < 0.05) and HbA1c level (R = 0.31; p < 0.05) and a moderate negative correlation with eGFR (R = –0.51; p < 0.01). In group 2, a positive weak correlation of Pro-ADM with age (R = 0.12; p < 0.01); duration of T2DM (R = 0.28; p < 0.05); cholesterol (R = 0.06; p > 0.05), and urea levels (R = 0.06; p > 0.05) was observed. There was a positive moderate correlation with HbA1c (R = 0.31; p < 0.05); creatinine (R = 0.47; p < 0.01) levels, and ACR (R = 0.32; p < 0.01). A mode­rate inverse correlation with eGFR was also found (R = –0.33; p < 0.01). In group 3, a posi­tive weak correlation of Pro-ADM with the duration of T2DM (R = 0.24; p < 0.05), and total cholesterol level (R = 0.19; p > 0.05) was observed. A positive mode­rate correlation with age (R = 0.53; p < 0.01); HbA1c (R = 0.33; p < 0.05), urea (R = 0.42; p > 0.05), creatinine levels (R = 0.34; p < 0.01), and ACR (R = 0.36; p < 0.01) was found. There was also a negative strong correlation with eGFR (R = –0.71; p < 0.01). Conclusions. We found a significant increase in Pro-ADM level in patients with T2DM depending on the progression of DKD. The revealed correlations between Pro-ADM and clinical parameters of T2DM and the functional state of the kidneys indicate that the level of Pro-ADM is associated with the progression of DKD. These results show the importance of identifying Pro-ADM as a potential marker for assessing the progression of renal impairment in patients with T2DM.https://iej.zaslavsky.com.ua/index.php/journal/article/view/1404type 2 diabetes mellitusdiabetic kidney diseasefunctional state of kidneysproadrenomedullin
spellingShingle A.M. Urbanovych
A.P. Vereshchynska
Role of proadrenomedullin in the progression of diabetic kidney disease in patients with type 2 diabetes mellitus
Mìžnarodnij Endokrinologìčnij Žurnal
type 2 diabetes mellitus
diabetic kidney disease
functional state of kidneys
proadrenomedullin
title Role of proadrenomedullin in the progression of diabetic kidney disease in patients with type 2 diabetes mellitus
title_full Role of proadrenomedullin in the progression of diabetic kidney disease in patients with type 2 diabetes mellitus
title_fullStr Role of proadrenomedullin in the progression of diabetic kidney disease in patients with type 2 diabetes mellitus
title_full_unstemmed Role of proadrenomedullin in the progression of diabetic kidney disease in patients with type 2 diabetes mellitus
title_short Role of proadrenomedullin in the progression of diabetic kidney disease in patients with type 2 diabetes mellitus
title_sort role of proadrenomedullin in the progression of diabetic kidney disease in patients with type 2 diabetes mellitus
topic type 2 diabetes mellitus
diabetic kidney disease
functional state of kidneys
proadrenomedullin
url https://iej.zaslavsky.com.ua/index.php/journal/article/view/1404
work_keys_str_mv AT amurbanovych roleofproadrenomedullinintheprogressionofdiabetickidneydiseaseinpatientswithtype2diabetesmellitus
AT apvereshchynska roleofproadrenomedullinintheprogressionofdiabetickidneydiseaseinpatientswithtype2diabetesmellitus